INNOVAZIONI TERAPEUTICHE IN ONCOLOGIA MEDICA CAGLIARI 23-24 GIUGNO 2005 LE TERAPIE A TARGET MOLECOLARE: UNA EVOLUZIONE EPOCALE DELLA TERAPIA ANTINEOPLASTICA.

Slides:

Advertisements

Similar presentations

TK Inhibitors in NSCLC Rossana Berardi

Advertisements

Rome, 11 april 2008 Progress in treatment of pancreatic cancer Mariacristina Di Marco S.S.D. Oncologia Medica Prof.G.Biasco Istituto di Ematologia ed Oncologia.

Gynecologic Oncology Group Gynecologic Oncology Group Uterine Corpus Trials: GCIG David Scott Miller, M.D., F.A.C.O.G., F.A.C.S. Director and Dallas Foundation.

Metastatic Gastric Cancer

Treatment in Advanced Non-Small Cell Lung Cancer.

William J. Gradishar MD, FACP Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center For Women's Cancer Care Robert H. Lurie Comprehensive.

Optimizing the Delivery of Combined Modality Therapy Philip Bonomi, MD.

Staging. Treatment by Stage For early stage lung cancers, surgery or radiation alone For larger tumors (>4 cm) and N+, chemotherapy should be added.

A Phase III Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Inhibitor Gefitinb in Completely Resected Stage.

Clinical developmentDiscovery Typical development timeline Typically – 8 yearsTypically 7 years.

21th WCC, Shenzhen, China, Aug 19, 2010 Guo-Liang Jiang, MD, FACR Min Fan, MD, Jiayan Chen, MD Fudan University Shanghai Cancer Center Combination of radiation.

New Perspectives in Cancer Therapy Óren Smaletz Programa de Oncologia Hospital Israelita Albert Einstein.

CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.

Adjuvant therapy for renal cell carcinoma Dr.Mina Tajvidi oncologist.

Clinical Division of Oncology Department of Medicine I Medical University of Vienna, Austria Monoclonal antibodies in solid tumors.

Highlights in the Management of Breast Cancer Rome, May 25-26, 2007 CLINICAL CASE Dott.ssa Marinella Zilli Cattedra di Oncologia Medica Università “G.

Phase III Study Comparing Gemcitabine plus Cetuximab versus Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma Southwest.

Molecular Cancer Targets Wester H Clin Cancer Res 2007;13:

First-Line TKI Use in EGFR Mutation-Positive NSCLC

LUNG CANCER: ASCO 2006 TOPICS Adjuvant therapy Clinical studies Meta-analysis ChemoXRT for stage III disease Advances in stage IV NSCLC New agents Predictive.

Advanced Cancer Topics Journal Review 4/16/2009 AD.

Clinicaloptions.com/oncology Expert Insight Into the First-line Treatment of Metastatic Colorectal Cancer N016966: Efficacy Results  PFS significantly.

An update on biological therapies in colorectal cancer Mount Vernon Cancer Network Sept 05 Mark Harrison.

Lee Ellis, MD, UT MDACC Anti-VEGF Therapy Goes Mainstream Lee M. Ellis, MD UT MD Anderson Cancer Center Houston, TX ASCO 2005 “Advancing the science of.

Adjuvant Therapy of Colon Cancer 2005 Daniel G. Haller, M.D. Abramson Cancer Center at the University of Pennsylvania Philadelphia PA.

Lung cancer perspectives. Targeted therapy : one for all or a few for one ? Miklos Pless, Winterthur

Targeted Therapy in Head & Neck Cancer Anti-EGFR Treatment Jan B. Vermorken, MD, PhD University Hospital Antwerp Edegem, Belgium.

Systemic Treatment of Metastatic Colorectal Cancer: Living with a Moving Landscape Neal J. Meropol, MD Fox Chase Cancer Center May 16, 2005.

Treatment for metastatic bladdercancer (chemotherapy&radiotherapy) Dr.Mina Tajvidi oncologist.

Critical Concepts in the Use of Combination Chemotherapy With Targeted Agents Lee M. Ellis, MD The University of Texas MD Anderson Cancer Center.

Xeloda ® monotherapy in pancreatic cancer: phase II study  42 patients with advanced/metastatic pancreatic cancer received intermittent Xeloda 1,250mg/m.

 Angiogenesis Signaling Cascades EGFR PI3K MAPK Nucleus Gene Activation Cell Cycle Progression M G1G1 S G2G2 Fos P P MAPK = mitogen-activated protein.

Fernando Cotait Maluf Diretor do Departamento de Oncologia Clínica Centro de Oncologia-Hospital São José Fernando Cotait Maluf Diretor.

CI-1 Tarceva ® (erlotinib) Tablets in Combination with Gemcitabine as a 1st-line Treatment of Pancreatic Cancer Presentation to the Oncologic Drugs Advisory.

Dr Francis Daniel, MB. ChB, FFR-RCSI, FRCR. Consultant in Clinical Oncology

FOLFOX4 with or without Bevacizumab in Previously Treated Advanced Colorectal Cancer: Results from ECOG-E3200 Lee M Ellis, MD Colorectal Cancer Update.

Adjuvant Therapy of Colon Cancer: Where are we now ? Leonard Saltz, MD Memorial Sloan Kettering Cancer Center New York, NY.

Journal Club Dr. Eyad Al-Saeed Radiation Oncology 12 January, 2008.

Dr Marco Matos Medical Oncologist Gold Coast Cancer Care, Gold Coast University Hospital and, Pacific Private Oncology Group.

North Central Cancer Treatment Group Randomized Phase II Trial of Panitumumab, Erlotinib, and Gemcitabine (PGE) versus Erlotinib-Gemcitabine (GE) in Patients.

Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.

Adjuvant and Neoadjuvant Therapy in Non- Small Cell Lung Cancer Seminars in Oncology 2oo5;32 (suppl 2):S9-S15 Kyung Hee Medical Center Department of Thoracic.

Therapy Targeted د. نورس نبيل جعفر أخصائية في علم الأورام طبيبة مشرفة بمشفى ابن النفيس مؤتمر نقابة أطباء سورية العلمي الأول.

Estimation of drug cost avoidance (DCA) and pathology cost avoidance (PCA) through participation in NCIC clinical trials group phase III trials Patricia.

Cancer targeted therapy José Carlos Machado. Cancer progression.

Empowering induction therapy for locally advanced head and neck cancer A. Argiris1* & M. V. Karamouzis2 1Division of Hematology–Oncology, Department of.

Esophageal Cancer: A Critical Evaluation of Systemic Second-Line Therapy Christiane Maria Rosina Thallinger, Markus Raderer, and Michael Hejna J Clin Oncol.

종양혈액내과 R4 고원진 / pf. 김시영 Rectal cancer : state of the art in 2012 Curr Opin Oncol 2012, 24:441–447.

Dr. Marco Matos JOURNAL CLUB GCUH 4/07/14.

Clinical and Research Updates in Gynecologic Oncology

¿Qué ver en ASCO 2017?.

Recent Advances in NSCLC Treatment

Management of metastatic and recurrent head and neck cancer

CHEMO-IMMUNO-TARGET THERAPIES

Cetuximab Drugbank ID : DB00002

Systemic treatment of advanced cutaneous squamous and basal cell carcinomas.

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Strategies for the Management of EGFR TKI Resistance in Advanced NSCLC

Colorectal Cancer: Current “Standard” Uses for Molecular Testing

Chapter 3 Treatment guidelines for NSCLC that does not have targetable driver mutations.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Practical Guidance on the Management of Pan-Negative NSCLC

KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer treated with FOLFIRI with or without cetuximab: The.

Discussion on Abstracts 362, 363, 364, 365, and 366 or…We still have a lot to learn about colorectal cancer Johanna Bendell, MD Director, GI Oncology Research.

Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) +/- cetuximab for patients with untreated metastatic adenocarcinoma of the.

Activity Goals. Clinical Considerations in the Use of Checkpoint Inhibitors for Genitourinary Cancers.

Physiologic vs Chronologic Age

Physiologic vs Chronologic Age

Updates in Best Practices in Non-Small Cell Lung Cancer

Presentation transcript:

INNOVAZIONI TERAPEUTICHE IN ONCOLOGIA MEDICA CAGLIARI GIUGNO 2005 LE TERAPIE A TARGET MOLECOLARE: UNA EVOLUZIONE EPOCALE DELLA TERAPIA ANTINEOPLASTICA GIOVANNI MANTOVANI CATTEDRA DI ONCOLOGIA MEDICA UNIVERSITA’ DEGLI STUDI DI CAGLIARI

The so-called molecularly targeted anticancer treatment is based on compounds that interefere with cell targets directly connected with pathogenetic events. Such therapies are expected to target specifically tumor cells, thus allowing for strong anticancer effects and minimal toxicities The so-called molecularly targeted anticancer treatment is based on compounds that interefere with cell targets directly connected with pathogenetic events. Such therapies are expected to target specifically tumor cells, thus allowing for strong anticancer effects and minimal toxicities THE MOLECULARLY TARGETED ANTICANCER TREATMENT

The possible targets are represented by: The possible targets are represented by: the interaction between the ligand (growth factor) and its specific receptor with the consequent activation of a cascade of biochemical events leading to the transduction of the cell proliferating signal from the membrane surface to the nucleus; the interaction between the ligand (growth factor) and its specific receptor with the consequent activation of a cascade of biochemical events leading to the transduction of the cell proliferating signal from the membrane surface to the nucleus; the cell cycle checkpoint, acting by a negative counterregulation the cell cycle checkpoint, acting by a negative counterregulation the apoptosis, by using proapoptotic molecules the apoptosis, by using proapoptotic molecules

(neo)angiogenesisthrough angiogenesis inhibitors (neo)angiogenesisthrough angiogenesis inhibitors the immune compartment of the host, by modulating his immune response the immune compartment of the host, by modulating his immune response

EGFR INHIBITION (Harari PM, Huang SM. Clin Can Res 10:428, 2004)

*HRPC: hormone-refractory prostate cancer *

 Erlotinib (Tarceva) EGGR (TK INHIB) (TK INHIB)

GEFITINIB MONOTHERAPY (3rd LINE IN NSCLC) ISEL study in adjuvant setting: negative Colorectal cancer, breast cancer, brain tumor ERLOTINIB MONOTHERAPY IN RECURRENT NSCLC after failure of at least one prior chemotherapy regimen (NCIC CTG study) BR.21: a randomised phase III trial of Tarceva following chemotherapy in advanced NSCLC MONOTHERAPY IN BAC (Yoshimura A, Gan To Kagaku Ryoho Mar;31(3): ) IN COMBINATION WITH CHEMOTHERAPY IN ADVANCED PANCREATIC CANCER (Moore MJ, NCI-CTG – Study PA.3, ASCO 2005) MAIN CURRENT CLINICAL APPLICATIONS 2005

ERLOTINIB + BEVACIZUMAB in advanced refractory NSCLC ERLOTINIB + BEVACIZUMAB in metastatic breast cancer (phase II study) ERLOTINIB + BEVACIZUMAB in metastatic RCC ERLOTINIB combined with CISPLATIN and GEMCITABINE in advanced NSCLC (TALENT STUDY: negative) ERLOTINIB combined with CARBOPLATIN and PACLITAXEL in advanced NSCLC (TRIBUTE STUDY: negative)

CETUXIMAB CETUXIMAB + HIGH DOSE RADIATION IN ADVANCED HEAD AND NECK SCC CETUXIMAB + HIGH DOSE RADIATION IN ADVANCED HEAD AND NECK SCC CETUXIMAB +/- IRINOTECAN IN METASTATIC REFRACTORY CRC (BOND I TRIAL) CETUXIMAB +/- IRINOTECAN IN METASTATIC REFRACTORY CRC (BOND I TRIAL) FOLFOX/FOLFIRI +/- CETUXIMAB FIRST LINE IN METASTATIC CRC (CALGB TRIAL) FOLFOX/FOLFIRI +/- CETUXIMAB FIRST LINE IN METASTATIC CRC (CALGB TRIAL) MAIN CURRENT CLINICAL APPLICATIONS 2005

BEVACIZUMAB PHASE III TRIALS Bolus IFL +/- BEVACIZUMAB FIRST LINE IN METASTATIC CRC (Hurwitz, NEJM 2004) BEVACIZUMAB +/- FOLFOX4 vs FOLFOX4 SECOND LINE IN METASTATIC CRC (E3200) PACLITAXEL + CARBOPLATIN +/- BEVACIZUMAB IN ADVANCED NON SQUAMOUS NSCLC (E4599) CAPEOX/FOLFOX +/- BEVACIZUMAB FIRST LINE IN METASTATIC CRC (SWOG 0303) BEVACIZUMAB + CETUXIMAB +/- IRINOTECAN THIRD LINE IN METASTATIC CRC (BOND II TRIAL) BEVACIZUMAB IN RCC

*HRPC: hormone-refractory prostate cancer *

Thank you for your attention and interest!